EUDA Health, GO POSB, Shenzhen Innovation Plan Cell Therapy Collaboration

MT Newswires Live07-30

EUDA Health (EUDA) said Thursday that GO POSB Organoids and Shenzhen Innovation Immunotechnology plan to combine GO POSB's induced pluripotent stem cell platform and tumor organoid bank with Shenzhen Innovation Immunotechnology's natural killer and NK-TCR cell engineering and manufacturing capabilities.

The proposed collaboration would explore the development, production and commercialization of off-the-shelf cell therapies for wellness and cancer applications, subject to definitive agreements and regulatory approvals.

EUDA said it plans to fund and coordinate the program and support commercialization and global market access under a nonbinding memorandum of understanding signed July 15.

Price: 18.50, Change: -1.85, Percent Change: -9.09

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655604809?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655604809","market":"nz","top_or_hot":-1,"title":"EUDA Health, GO POSB, Shenzhen Innovation Plan Cell Therapy Collaboration","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/EUDA\">EUDA Health</a> (EUDA) said Thursday that GO POSB Organoids and Shenzhen Innovation Immunotechnology plan to combine GO POSB's induced pluripotent stem cell platform and tumor organoid bank with Shenzhen Innovation Immunotechnology's natural killer and NK-TCR cell engineering and manufacturing capabilities.</p><p>The proposed collaboration would explore the development, production and commercialization of off-the-shelf cell therapies for wellness and cancer applications, subject to definitive agreements and regulatory approvals.</p><p>EUDA said it plans to fund and coordinate the program and support commercialization and global market access under a nonbinding memorandum of understanding signed July 15.</p><p>Price: 18.50, Change: -1.85, Percent Change: -9.09</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EUDA Health, GO POSB, Shenzhen Innovation Plan Cell Therapy Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEUDA Health, GO POSB, Shenzhen Innovation Plan Cell Therapy Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-30 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/EUDA\">EUDA Health</a> (EUDA) said Thursday that GO POSB Organoids and Shenzhen Innovation Immunotechnology plan to combine GO POSB's induced pluripotent stem cell platform and tumor organoid bank with Shenzhen Innovation Immunotechnology's natural killer and NK-TCR cell engineering and manufacturing capabilities.</p><p>The proposed collaboration would explore the development, production and commercialization of off-the-shelf cell therapies for wellness and cancer applications, subject to definitive agreements and regulatory approvals.</p><p>EUDA said it plans to fund and coordinate the program and support commercialization and global market access under a nonbinding memorandum of understanding signed July 15.</p><p>Price: 18.50, Change: -1.85, Percent Change: -9.09</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0385154629.USD","symbol_name":"贝莱德营养科学基金A2","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2655604809","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655604809","pubTimestamp":1785423056,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"EUDA Health  said Thursday that GO POSB Organoids and Shenzhen Innovation Immunotechnology plan to combine GO POSB's induced pluripotent stem cell platform and tumor organoid bank with Shenzhen Innovation Immunotechnology's natural killer and NK-TCR cell engineering and manufacturing capabilities.The proposed collaboration would explore the development, production and commercialization of off-the-shelf cell therapies for wellness and cancer applications, subject to definitive agreements and regulatory approvals.EUDA said it plans to fund and coordinate the program and support commercialization and global market access under a nonbinding memorandum of understanding signed July 15.Price: 18.50, Change: -1.85, Percent Change: -9.09","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0385154629.USD":"贝莱德营养科学基金A2","BK4196":"保健护理服务","BK4113":"食品零售","GO":"Grocery Outlet Holding","EUDA":"EUDA Health Holdings Limited","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H"},"translate_title":"EUDA Health、GO POSB、深圳创新计划细胞治疗合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GO":1.5,"EUDA":1.5},"content_text":"EUDA Health (EUDA) said Thursday that GO POSB Organoids and Shenzhen Innovation Immunotechnology plan to combine GO POSB's induced pluripotent stem cell platform and tumor organoid bank with Shenzhen Innovation Immunotechnology's natural killer and NK-TCR cell engineering and manufacturing capabilities.The proposed collaboration would explore the development, production and commercialization of off-the-shelf cell therapies for wellness and cancer applications, subject to definitive agreements and regulatory approvals.EUDA said it plans to fund and coordinate the program and support commercialization and global market access under a nonbinding memorandum of understanding signed July 15.Price: 18.50, Change: -1.85, Percent Change: -9.09","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655604809","isCrawlerRequest":true}